
P16-489 | DEVOTE
NCT03310190
Devote
Study to Describe the Management and the Use of Healthcare Resources in Patients With Chronic Lymphocytic Leukemia (CLL) Initiating Venetoclax in Routine Clinical Practice (DEVOTE)
Status:
Closed to Accrual

Observational
Phase

N/A
Line of Therapy

Any Stage
Disease Stage

Biomarker(s)
N/A
Investigational
Product
Venetoclax
Antineoplastic Agent; BCL-2 Inhibitor (p.o.)
Treatment Arms
o Participants receiving venetoclax